Hong Kong stock anomaly | Junshi Biosciences (01877.HK) rose more than 10% JT118 received a drug clinical trial approval letter, and the company's multiple research achievements were selected for the WCLC.

According to the 36Kr Finance APP, China Everbright (01877.HK) rose by more than 10%, as of the time of writing, it has increased by 11.03% to 34.22 Hong Kong dollars, with a turnover of 516 million Hong Kong dollars.